Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | PYGB | P11216 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228011 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2817760 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL14199486 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6142431 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13497166 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL18533110 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9999673 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL12154805 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL8045018 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9843877 | 1.00 | OGA (0.37) | OGAPIM1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643337-B1 | PROCESS FOR THE PREPARATION OF (2R,3S)-2-(HYDROXYMETHYL) -5-METHOXYTETRAHYDROFURAN-3-OL FREE OF PYRANOSE COMPOUNDS | JOHNSON MATTHEY PLC (GB) | 2018-02-21 | — | — | EP | claimed |
| US-20140142296-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-2-(HYDROXYMETHYL)-5-METHOXYTETRAHYDROFURAN-3-OL AND ACETYLATED DERIVATIVES THEREOF, FREE OF PYRANOSE COMPOUNDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-05-22 | — | — | US | claimed |
| US-20100249394-A1 | PROCESSES FOR PRODUCING DECITABINE | ALBEMARLE CORPORATION (US) | 2010-09-30 | — | — | US | claimed |
| US-5585252-A | CATALYTIC ACYLATION OF ALCOHOLS | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | claimed |
| US-20240400581-A1 | Process for Preparing a Macrocyclic Compound Having ENT1 Inhibiting Activity | iTeos Belgium SA (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | iTeos Belgium SA (BE) | 2024-11-07 | — | — | US | disclosed |
| EP-4413003-A1 | PROCESSES FOR PREPARING A MACROCYCLIC COMPOUND HAVING ENT1 INHIBITING ACTIVITY | iTeos Belgium SA (BE) | 2024-08-14 | — | — | EP | disclosed |
| EP-4413004-A1 | MACROCYCLIC COMPOUNDS HAVING ENT1 INHIBITING ACTIVITY | iTeos Belgium SA (BE) | 2024-08-14 | — | — | EP | disclosed |
| CN-118076610-A | Macrocyclic compounds with ENT1 inhibitory activity | ITEOS比利时公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230220384-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-07-13 | — | — | US | disclosed |
| US-20230220384-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-07-13 | — | — | US | disclosed |
| EP-0380362-A1 | Biosynthetic uses of thermostable proteases | GENEX CORPORATION (a Delaware corporation) (US) | 1990-08-01 | — | — | EP | disclosed |
| EP-0357009-A2 | Method of resolution of hydroxy-cyclopentenones using a lipase and transacylation agents | G.D. Searle & Co. (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0357571-A2 | Pyrimidine nucleosides | Medivir Aktiebolag (SE) | 1990-03-07 | — | — | EP | disclosed |
| US-4898936-A | ANTITUMOR AGENTS | PCR, INC. (US) | 1990-02-06 | — | — | US | disclosed |
| WO-1989012061-A1 | PYRIMIDINE NUCLEOSIDES AND INTERMEDIATES | MEDIVIR AB (SE) | 1989-12-14 | — | — | WO | disclosed |
| EP-0195805-A4 | PROCESS FOR MAKING A 2-DEOXYURIDINE. | SCM CORP (US) | 1987-07-09 | — | — | EP | disclosed |
| EP-0195805-A1 | PROCESS FOR MAKING A 2-DEOXYURIDINE | PCR, Inc. (US) | 1986-10-01 | — | — | EP | disclosed |
| WO-1986001801-A1 | PROCESS FOR MAKING A 2-DEOXYURIDINE | SCM CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | ENTPD5, ENTPD1, ENTPD8 | OGA 1712/4885PIM1 3105/4885CSNK2A2 3883/4885 |
| US-20140142296-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-2-(HYDROXYMETHYL)-5-METHOXYTETRAHYDROFURAN-3-OL AND ACETYLATED DERIVATIVES THEREOF, FREE OF PYRANOSE COMPOUNDS | DERA, MPG, TYMS | OGA 196/4885PIM1 1982/4885CSNK2A2 3808/4885 |
| US-20240400581-A1 | Process for Preparing a Macrocyclic Compound Having ENT1 Inhibiting Activity | ENTPD5, ENTPD1, ENTPD8 | OGA 1310/4885PIM1 3366/4885CSNK2A2 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.